• <table id="gigg0"></table>
  • west china medical publishers
    Keyword
    • Title
    • Author
    • Keyword
    • Abstract
    Advance search
    Advance search

    Search

    find Keyword "肺表面活性蛋白D" 3 results
    • Changes of Pulmonary Surfactant Protein D in Serum and Lung Tissue of Rats with Chronic Obstructive Pulmonary Disease

      Objective To investigate the relationship of pulmonary surfactant protein D( SP-D) with chronic obstructive pulmonary disease ( COPD) by measuring SP-D level in serum and lung tissue of rats with COPD.Methods The rat COPD model was established by passive smoking as well as intratracheal instillation of lipopolysaccharide ( LPS) . Thirty male SD rats were randomly divided into a control group, a LPS group, and a COPD group( n =10 in each group) . The pathologic changes of lung tissue and airway were observed under light microscope by HE staining. Emphysema changes were evaluated by mean linear intercept ( MLI) of lung and mean alveolar number ( MAN) . The level of SP-D in serum was measured by enzymelinked immunosorbent assay ( ELISA) . The expression of SP-D in lung tissue was detected by Western-blot and immunohistochemistry.Results The MLI obviously increased, and MAN obviously decreased in the COPD group compared with the control group ( Plt;0.05) . There was no significant difference in the MLI and MAN between the LPS group and the control group ( Pgt;0.05) . The serum SP-D level was ( 49.59 ±2.81) ng/mL and ( 53.21±4.17) ng/mL in the LPS group and the COPD group, which was significantly higher than that in the control group [ ( 42.14±2.52) ng/mL] ( Plt;0.05) . The expression of SP-D in lung tissue was 0.56±0.01 and 0.63±0.01 in the LPS group and the COPD group, which was also obviously ber than that in the control group ( 0.39 ±0.01) ( Plt;0.05) .Meanwhile the SP-D levels in serumand lung tissue were higher in the COPD group than those in the LPS group ( Plt;0.05) . The levels of SP-D between serum and lung tissue were positively correlated in all three groups ( r=0.93, 0.94 and 0.93, respectively, Plt;0.01) .Conclusion Both the SP-D level in serum and in lung tissue increase significantly in COPD rats and correlate well each other, which suggests that SP-D may serve as a biomarker of COPD.

      Release date: Export PDF Favorites Scan
    • 慢性阻塞性肺疾病急性加重患者血清和呼出氣冷凝液中肺表面活性蛋白D與趨化因子配體18的表達及其臨床意義

      目的探索肺表面活性蛋白D (SP-D)、趨化因子配體18(CCL18)表達在慢性阻塞性肺疾病(簡稱慢阻肺)急性加重患者病情監測中的意義。 方法選取2012年4月至2013年4月慢阻肺急性加重患者22例(慢阻肺急性加重組),健康吸煙者22例(對照組)。記錄研究對象的年齡、煙齡、體重指數(BMI)、肺功能檢查結果。收集慢阻肺急性加重組治療前、后及對照組的血清和呼出氣冷凝液(EBC),采用酶聯免疫吸附試驗(ELISA)檢測各研究對象血清和EBC中SP-D、CCL18表達。分析SP-D、CCL18表達與年齡、煙齡、BMI及肺功能的相關性。 結果與對照組比較,慢阻肺急性加重組患者治療前血清及EBC中SP-D表達明顯升高[(353.1±221.7) ng/mL比(207.3±171.6) ng/mL,(2.6±1.1) ng/mL比(1.9±1.1) ng/mL,P<0.05],而治療后血清及EBC中SP-D表達比較,差異無統計學意義(P>0.05)。慢阻肺急性加重組治療前后血清和EBC中SP-D表達比較,差異無統計學意義(P>0.05)。與對照組比較,慢阻肺急性加重組治療前EBC中CCL18表達顯著降低[(14.2±5.2) pg/mL比(19.1±5.6) pg/mL,P<0.05)],而治療后EBC中CCL18表達差異無統計學意義(P>0.05);慢阻肺急性加重組治療前EBC中CCL18表達低于治療后[(14.2±5.2) pg/mL比(19.4±7.0) pg/mL,P<0.05]。各組研究對象血清中CCL18表達比較,差異均無統計學意義(P>0.05)。相關性分析結果表明:血清中SP-D表達與煙齡正相關(r=0.34,P<0.05);與第1秒用力呼氣容積(FEV1)、FEV1占預計值百分比(FEV1% pred)、用力肺活量(FVC)、FEV1與FVC比值(FEV1/FVC)負相關(r分別為-0.35、-0.34、-0.31、-0.36,P<0.05);與年齡、BMI均不相關(P>0.05)。EBC中SP-D表達與煙齡正相關(r=0.11,P<0.05);與FEV1/FVC負相關(r=-0.37,P<0.05);與年齡、BMI、FEV1、FEV1% pred、FVC均不相關(P>0.05)。血清和EBC中CCL18表達和年齡、煙齡、BMI、FEV1、FEV1% pred、FVC及FEV1/FVC均不相關(P>0.05)。 結論EBC和血清中SP-D、CCL18表達變化在慢阻肺急性加重病情監測中具有一定價值,而且EBC中SP-D、CCL18表達變化在慢阻肺急性加重患者病情監測中更具獨特的優勢。

      Release date: Export PDF Favorites Scan
    • Comparative study of serum POSTN, KL-6, SP-A, and SP-D as biomarkers of idiopathic pulmonary fibrosis

      Objective To investigate the impact and mechanisms of periostin (POSTN), Krebs von den Lungen-6 (KL-6), pulmonary surfactant protein A (SP-A), and pulmonary surfactant protein D (SP-D) on the diagnosis and disease assessment of idiopathic pulmonary fibrosis (IPF), and conduct a comparative analysis. Methods From October 2022 to October 2023, a total of 55 patients diagnosed with IPF and treated at the Third Affiliated Hospital of Anhui Medical University were enrolled as an IPF group. Additionally, 30 patients with bacterial pneumonia and 30 healthy individuals undergoing concurrent health examinations during the same period were selected as a pneumonia control group and a healthy control group, respectively. All participants underwent enzyme-linked immunosorbent assay to measure serum levels of POSTN, KL-6, SP-A, and SP-D, along with pulmonary function tests. The IPF patients also underwent high-resolution computed tomography (HRCT) and echocardiography to quantify HRCT scores and pulmonary artery systolic pressure (PASP). Receiver operating characteristic (ROC) curves were plotted to analyze the significance of serum POSTN, KL-6, SP-A, and SP-D levels in IPF diagnosis. Pearson and Spearman correlation tests were used to analyze the relationships between these biomarkers and pulmonary function, PASP, and HRCT scores. Results Serum concentrations of POSTN, KL-6, SP-A, and SP-D were significantly elevated in the IPF group compared with the pneumonia group and the healthy controls (P<0.05), while serum levels of SP-A and SP-D were notably higher in the pneumonia group compared with the healthy control group (P<0.05). Within the IPF group, serum POSTN levels were negatively correlated with forced expiratory volume in the first second as a percentage of predicted value (FEV1%pred) and diffusion capacity of the lung for carbon monoxide as a percentage of predicted value (DLCO%pred) (P<0.05); KL-6 and SP-D levels were also negatively correlated with FEV1%pred, forced vital capacity as a percentage of predicted value (FVC%pred), and DLCO%pred (P<0.05); and the concentration of SP-A was negatively correlated with DLCO%pred and positively correlated with PASP (P<0.05). Additionally, serum levels of POSTN, KL-6, and SP-A in the IPF group showed significant positive associations with HRCT scores (P<0.01). Conclusions POSTN is a valuable serum biomarker for IPF, exhibiting the highest sensitivity and specificity among the four serum markers, with diagnostic performance superior to KL-6, SP-A, and SP-D. POSTN, KL-6, SP-A, and SP-D can all be used for the diagnosis and assessment of IPF.

      Release date:2025-03-25 01:25 Export PDF Favorites Scan
    1 pages Previous 1 Next

    Format

    Content

  • <table id="gigg0"></table>
  • 松坂南